TMCnet - World's Largest Communications and Technology Community



Oasis Diagnostics® Announces Grant Award from the Michael J. Fox Foundation for Parkinson's Disease
[January 08, 2014]

Oasis Diagnostics® Announces Grant Award from the Michael J. Fox Foundation for Parkinson's Disease

VANCOUVER, Wash. --(Business Wire)--

Oasis Diagnostics® Corporation [OASIS] is the recipient of a research award from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to validate OASIS' development of a non-invasive, saliva-based, rapid test for Parkinson's disease detection and diagnosis. OASIS will collaborate with Dr. Charles Adler's group at the Mayo Clinic in Scottsdale, Arizona to study proprietary biomarkers in saliva that are the subject of an exclusive license held by OASIS from Danish researchers.

Research has shown that 50 salivary biomarkers are contributory to Parkinson's disease, but that as few as three can lead to accurate diagnosis using the OASIS' VerOFy® platform. The VerOFy® Rapid Test Platform is an enabling technology for rapid, point-of-care diagnosis using saliva specimens. In the project supported by MJFF, initial work will be carried out to confirm that VerOFy® is able to detect specific concentrations of each of three biomarkers that collectively provide a high degree of accuracy (sensitivity and specificity) for Parkinson's disease detection.

Diagnosis of Parkinson's disease is very difficult due to dependence on clinical examination and the current lack of suitable diagnostic biomarkers. Tests that do provide some evidence of disease presence - such as measurement of cerebrospinal biomarkers and imaging techniques - are expensive and/or invasive in nature. A saliva-based diagnosic test would be a great benefit to the millions of individuals living with Parkinson's disease, and the many more who will become at risk as the population ages. Additionally, validation of Parkinson's biomarkers could aid clinical trials of disease-modifying treatments by allowing for study participant stratification and faster testing of a therapy's efficacy.

Founded in 2007 by Dr. Paul D. Slowey, OASIS develops, manufactures and commercializes saliva diagnostic and standardized collection tools with the goal of meeting a worldwide and increasing demand for fast, accurate, convenient and painless saliva tests.

Several unique saliva tests are currently under development in the VerOFy® platform device including tests for stress [cortisol], which is the subject of an NIH Phase II SBIR award, testosterone and estradiol. VerOFy® provides quantitative biomarker assessment and may be applied to a multitude of diseases, disease states or biomarkers for use in any setting where immediate results are required.

About Oasis Diagnostics® Corporation

Oasis Diagnostics® is an emerging Vancouver, WA based company focused on the design, development and commercialization of salivary diagnostic tools with applications at the point-of-care, in the laboratory and for molecular diagnostic testing. The Company has developed a series of oral technologies that are useful in areas such as general wellness, global health, drugs of abuse, infectious diseases, DNA and RNA collection, nucleic acid testing and protein characterization. The OASIS technologies are protected by a series of US and international patents.

Forward-Looking Statements

Portions of this press release may contain forward-looking statements regarding future events and undertakings. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially from any future performance suggested in such statements. OASIS does not undertake any obligation to publicly update any forward-looking statements as a result of new information, future events or otherwise. OASIS urges the reader to consider all of these risks, uncertainties and other factors carefully in evaluating these forward-looking statements made in this release and not to place undue reliance on such statements. As a result of these and other matters, including changes in facts, assumptions not being realized or other circumstances, our actual results may differ materially from those discussed in the forward-looking statements. The forward-looking statements included in this release are made only as of the date of this release, and we undertake no obligation to update it to reflect subsequent events or circumstances.

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy